Novo Nordisk (NVO) Stock Dips Despite Promising Childhood Obesity Trial Results
Novo Nordisk (NVO) stock dropped 1.92% after ending two heart drug trials, though semaglutide showed 40% of children aged 6-12 reversed obesity in trials.
The post Novo Nordisk (NVO) Stock Dips Despite Promising Childhood Obesity Trial Results appeared first on Blockonomi.
Source: Source: Blockonomi